跳转至内容
Merck
CN

E9406

表柔比星盐酸盐 盐酸盐

≥90% (HPLC)

别名:

4′-Epidoxorubicin hydrochloride, Epidoxorubicin hydrochloride

登录 查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C27H29NO11 · HCl
化学文摘社编号:
56390-09-1
分子量:
579.98
EC 号:
260-145-2
MDL编号:
MFCD00941448
UNSPSC代码:
51102829
PubChem化学物质编号:
329799084
NACRES:
NA.85

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

生物来源

synthetic

质量水平

100

方案

≥90% (HPLC)

表单

powder

颜色

red to deep red

溶解性

H2O: soluble

抗生素抗菌谱

neoplastics

作用机制

DNA synthesis | interferes
enzyme | inhibits

储存温度

−20°C

SMILES字符串

Cl.COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO

InChI

1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22-,27-;/m0./s1

InChI key

MWWSFMDVAYGXBV-FGBSZODSSA-N

正在寻找类似产品? 访问 产品对比指南

相关类别

应用

Epirubicin is used to inhibit topoisomerase II and DNA helicase activity. Epirubicin is used to study metastatic breast cancerand cardiac toxicity.

生化/生理作用

Cell-permeable anthracycline antitumor antibiotic. Antineoplastic. A stereoisomer of doxorubicin that exhibits reduced cardiotoxicity. Its antitumor actions are mediated by targeting topoisomerase II.
Epirubicin is antimitotic and cytotoxic. It inhibits nucleic acid and protein synthesis. Epirubicin may do so by forming complexes with DNA and intercalation between base pairs, by inhibiting topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, and by preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.

象形图

Health hazardExclamation mark
GHS08,GHS07

警示用语：

Danger

危险分类

Acute Tox. 4 Oral - Carc. 1B - Muta. 1B - Repr. 1B

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000496920
0000496928
0000496928
0000496920
0000473741

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Letícia Tiburcio Ferreira et al.
Antimicrobial agents and chemotherapy, 64(9) (2020-07-01)
Widespread resistance against antimalarial drugs thwarts current efforts for controlling the disease and urges the discovery of new effective treatments. Drug repositioning is increasingly becoming an attractive strategy since it can reduce costs, risks, and time-to-market. Herein, we have used
Aman U Buzdar et al.
The Lancet. Oncology, 14(13), 1317-1325 (2013-11-19)
Neoadjuvant chemotherapy with trastuzumab for patients with HER2-positive breast cancer can produce a pathological complete response in the breast in 30-65% of patients. We investigated the effect of the timing of trastuzumab administration with anthracycline and taxane neoadjuvant chemotherapy. This
P Fumoleau et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 17(1), 85-92 (2005-10-28)
The aim of the study was to evaluate and compare incidence and risk factors of left ventricular dysfunction (LVD) in early breast cancer patients receiving (E+) or not (E-) epirubicin-based adjuvant chemotherapy. Among eight FASG trials, 3577 assessable patients were
O Feher et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 16(6), 899-908 (2005-04-12)
This randomized, phase III study compared the efficacy and safety of first-line gemcitabine versus epirubicin in the treatment of postmenopausal women with metastatic breast cancer (MBC). Patients aged > or = 60 years (median 68 years) with clinically measurable MBC
Sarah N Hamilton et al.
International journal of radiation oncology, biology, physics, 87(4), 719-725 (2013-09-05)
To review the treatment and outcomes of patients with primary cutaneous B-cell lymphoma (CBCL). Clinical characteristics, treatment, and outcomes were analyzed for all patients referred to our institution from 1981 through 2011 with primary CBCL without extracutaneous or distant nodal
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持